US equities |
MU $969.63 ▲+4.40% SPCX $144.04 ▼-3.05% TSLA $398.88 ▼-2.11% META $615.11 ▼-0.82% SNDK $1,360.60 ▲+4.27% NVDA $218.27 ▲+0.15% SKHY $160.46 ▲+10.38% GOOGL $324.70 ▲+1.29%
FinancialContent

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

15.12 +0.28 (+1.89%)
Delayed Quote Updated: 10:26 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,922
Open 14.93
Bid (Size) 15.12 (100)
Ask (Size) 15.19 (300)
Prev. Close 14.84
Today's Range 14.72 - 15.15
52wk Range 6.732 - 23.19
Shares Outstanding 42,734,644
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead ↗
Almonty Industries, Kopin and Cullinan Therapeutics trade under $20, and each faces a near-term catalyst: China tungsten curbs, CES and a February FDA decision. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 34.8% below 52-week high
15.12
6.7352W Low 23.1952W High
1 Week 1.3% below 1-week high
13.861W Low 15.321W High

Cullinan Therapeutics, Inc. - Common Stock (CGEM) traded between $6.73 and $23.19 over the past 52 weeks and last traded at $15.12, 34.8% below its 52-week high. Over the past week it ranged between $13.86 and $15.32.

Past 12 Months
+1.5%
+1.1%
-13.5%
+18.0%
+49.4%
+87.6%
1W +$0.23
1M +$0.17
3M -$2.35
6M +$2.31
YTD +$5.00
1Y +$7.06

CGEM was +87.6% over the past year, +18.0% over six months, +49.4% year to date, +1.5% in the last week.

12 Months vs Market
CGEM
+87.6%
DIA
+10.2%
SPY
+12.5%
QQQ
+15.0%
IWM
+12.0%

Over the past 12 months CGEM returned +87.6% versus DIA (Dow) +10.2%, SPY (S&P 500) +12.5%, QQQ (Nasdaq 100) +15.0% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.05× 3-mo avg
Today 46,922 3-mo avg 899.9K
1W
499.1K
1M
869.1K
3M
899.9K
6M
974.8K
YTD
897.4K
1Y
945.0K

CGEM most recently traded 46,922 shares against a 3-month average daily volume of 899.9K.

More News

Read More
News headline image
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
From Taiho Oncology, Inc.
Via Business Wire
News headline image
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones ↗
Via Chartmill
Cullinan Therapeutics (NASDAQ:CGEM) Posts Narrower Q1 Loss, Eyes Key Clinical Data Catalysts ↗
Via Chartmill
News headline image
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 ↗
Via MarketBeat
News headline image
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
From Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. and Cullinan Therapeutics, Inc.
Via Business Wire
News headline image
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
From Taiho Oncology, Inc.
Via Business Wire
News headline image
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
From Taiho Oncology, Inc.
Via Business Wire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
Topics Stocks
News headline image
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
From Taiho Oncology, Inc.
Via Business Wire

Frequently Asked Questions

Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
The current price of Cullinan Therapeutics, Inc. - Common Stock is 15.12
When was Cullinan Therapeutics, Inc. - Common Stock last traded?
The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 10/28/26 10:26 AM ET
What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 646.15M
How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
Cullinan Therapeutics, Inc. - Common Stock has 646M shares outstanding.